These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 26423553)

  • 21. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.
    Ying R; Sharma M; Celum C; Baeten JM; van Rooyen H; Hughes JP; Garnett G; Barnabas RV
    Lancet HIV; 2016 Jun; 3(6):e275-82. PubMed ID: 27240790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.
    Long EF; Brandeau ML; Owens DK
    Ann Intern Med; 2010 Dec; 153(12):778-89. PubMed ID: 21173412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health economics modeling of antiretroviral interventions amongst HIV serodiscordant couples.
    Wu H; Yu Q; Ma L; Zhang L; Chen Y; Guo P; Xu P
    Sci Rep; 2021 Jul; 11(1):13967. PubMed ID: 34234232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.
    Meyer-Rath G; Pienaar J; Brink B; van Zyl A; Muirhead D; Grant A; Churchyard G; Watts C; Vickerman P
    PLoS Med; 2015 Sep; 12(9):e1001869. PubMed ID: 26327271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
    Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
    Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda.
    McCreesh N; Andrianakis I; Nsubuga RN; Strong M; Vernon I; McKinley TJ; Oakley JE; Goldstein M; Hayes R; White RG
    BMC Infect Dis; 2017 May; 17(1):322. PubMed ID: 28468605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An economic case for providing free access to antiretroviral therapy for HIV-positive people in South Australia.
    Heymer KJ; Wentzlaff-Eggebert M; Mortimer E; Wilson DP
    Sex Health; 2012 Jul; 9(3):220-6. PubMed ID: 22697138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy.
    Anis AH; Hogg RS; Wang XH; Yip B; Palepu A; Montaner JS; O'Shaughnessy MV; Schechter MT
    Pharmacoeconomics; 1998 Jun; 13(6):697-705. PubMed ID: 10179705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study.
    Olney JJ; Braitstein P; Eaton JW; Sang E; Nyambura M; Kimaiyo S; McRobie E; Hogan JW; Hallett TB
    Lancet HIV; 2016 Dec; 3(12):e592-e600. PubMed ID: 27771231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada.
    Lima VD; Hogg RS; Montaner JS
    PLoS One; 2010 Jun; 5(6):e10991. PubMed ID: 20539817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.
    Dutta A; Barker C; Kallarakal A
    PLoS Med; 2015 Nov; 12(11):e1001907; discussion e1001907. PubMed ID: 26599990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level programme evaluation.
    Lima VD; Zhu J; Barrios R; Toy J; Joy JB; Williams BG; Granich R; Wu Z; Wong J; Montaner JSG
    Lancet HIV; 2024 Jul; 11(7):e461-e469. PubMed ID: 38848736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
    Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
    J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why Maximizing Quality-Adjusted Life Years, rather than Reducing HIV Incidence, Must Remain Our Objective in Addressing the HIV/AIDS Epidemic.
    Nosyk B; Min JE; Zang X; Feaster DJ; Metsch L; Marshall BDL; Rio CD; Granich R; Schackman BR; Montaner JSG
    J Int Assoc Provid AIDS Care; 2019; 18():2325958218821962. PubMed ID: 30798657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis.
    Ward Z; Stone J; Bishop C; Ivakin V; Eritsyan K; Deryabina A; Low A; Cepeda J; Kelly SL; Heimer R; Cook R; Altice FL; Litz T; Terlikbayeva A; El-Bassel N; Havarkov D; Fisenka A; Boshnakova A; Klepikov A; Saliuk T; Deshko T; Vickerman P
    Lancet HIV; 2022 Jan; 9(1):e42-e53. PubMed ID: 34895484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
    Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.